BI-3406

Name: BI-3406
Brand: MedChemExpress
SKU: HY-125817
Rating: 5.0 (11 reviews)

Cat. No.: HY-125817 Purity: 99.95%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC₅₀ of 6 nM. BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits MAPK pathway signaling. BI-3406 has anticancer activity.

For research use only. We do not sell to patients.

The BI-3406 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.

CAS No. : 2230836-55-0

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 11 publication(s) in Google Scholar

11 Publications Citing Use of MCE BI-3406

Cell Migration/Invasion Assay

Cell Imaging/Staining

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

: BI-3406 purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2025 Mar 3;23(1):116. [Abstract]; Vehicle- (DMSO) or BI-3406-treated (1 µM) confluent WT primary MEFs were scratched with a micropipette tip and closure of the wounded area was recorded for 24 h by phase-contrast photomicroscopy.

: BI-3406 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Jan 2;85(1):101-117. [Abstract]; Western blot analysis of SOS1, pERK, GSPT1, and IKZF1/3 in NCI-H358 cells treated with SIAIS562055, SIAIS562092, or BI-3406 (10, 100, 1000 nM) for 24 hours.

: BI-3406 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Jan 2;85(1):101-117. [Abstract]; Antiproliferative effects of SIAIS562055 and BI-3406 for 120 hours on KRAS-WT (293T, BxPC-3) and KRAS-mutant (NCI-H358, GP2d, HPAF-II, and SW620) cells.

: BI-3406 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Jan 2;85(1):101-117. [Abstract]; MIA PaCa-2–xenografted mice received vehicle, SIAIS562055 (20 or 40 mg/kg/day), or BI-3406 (50 mg/kg, twice a day), then relative tumor weights were determined at indicated times.

: BI-3406 purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 Jul;44(7):1475-1486. [Abstract]; MIA PaCa-2 or NCI-H1373 cells were treated with 143D or a combination of drugs and stained with crystal violet for identifying monoclonal cell populations. 143D (10 nM), BI3406 (10 μM), trametinib (5 nM), SCH772984 (200 nM), Afatinib (10 nM).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Ras Isoform Specific Products:

View All Isoforms

K-Ras H-Ras N-Ras Ras

View All p38 MAPK Isoform Specific Products:

View All Isoforms

p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

KRAS-SOS1

6 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	106 nM Compound: 1; BI-3406	Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell growth Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell growth	[PMID: 38714262]
A549	IC₅₀	263 nM Compound: BI-3406	Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
ASPC1	IC₅₀	64.4 nM Compound: BI-3406	Antiproliferative activity against human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
DLD-1	IC₅₀	102 nM Compound: BI3406	Antiproliferative activity against human DLD-1 cells harboring G13D mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay Antiproliferative activity against human DLD-1 cells harboring G13D mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay	[PMID: 38206836]
DLD-1	IC₅₀	169 nM Compound: 1; BI-3406	Antiproliferative activity against human DLD-1 cells harboring KRAS G13D mutant assessed as inhibition of cell growth Antiproliferative activity against human DLD-1 cells harboring KRAS G13D mutant assessed as inhibition of cell growth	[PMID: 38714262]
K562	IC₅₀	1.422 μM Compound: BI-3406	Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CCK8 assay	[PMID: 38316747]
K562	IC₅₀	37 nM Compound: 6; BI-3406	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 37778239]
LoVo	IC₅₀	142 nM Compound: BI-3406	Antiproliferative activity against human LoVo cells harboring KRAS G13D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human LoVo cells harboring KRAS G13D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
MIA PaCa-2	IC₅₀	24.8 nM Compound: BI-3406	Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human MIA PaCa-2 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
MIA PaCa-2	IC₅₀	29 nM Compound: BI-3406	Antiproliferative activity against human MIA PaCa-2 cells incubated for 72 hrs by CCK8 assay Antiproliferative activity against human MIA PaCa-2 cells incubated for 72 hrs by CCK8 assay	[PMID: 38316747]
MIA PaCa-2	IC₅₀	30 nM Compound: 4; BI-3406	Antiproliferative activity against human MIA PaCa-2 cells harboring G12C mutant assessed as cell growth inhibition incubated for 7 days by Celltiter-Glo 3D cell viability assay Antiproliferative activity against human MIA PaCa-2 cells harboring G12C mutant assessed as cell growth inhibition incubated for 7 days by Celltiter-Glo 3D cell viability assay	[PMID: 36793426]
NCI-H358	IC₅₀	16.5 nM Compound: BI-3406	Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
NCI-H358	IC₅₀	24 nM Compound: BI3406	Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability	[PMID: 38206836]
NCI-H358	IC₅₀	26 nM Compound: BI3406	Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay	[PMID: 38206836]
NCI-H358	IC₅₀	26 nM Compound: BI3406	Antiproliferative activity against human NCI-H358 cells harboring G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay Antiproliferative activity against human NCI-H358 cells harboring G12C mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay	[PMID: 38206836]
NCI-H358	IC₅₀	90 nM Compound: 2; BI-3406	Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 5 days by celltiter-glo 3D assay Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as inhibition of cell proliferation incubated for 5 days by celltiter-glo 3D assay	[PMID: 38894918]
NCI-H441	IC₅₀	68 nM Compound: BI3406	Antiproliferative activity against human NCI-H441 cells harboring G12V mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay Antiproliferative activity against human NCI-H441 cells harboring G12V mutant assessed as inhibition of cell proliferation incubated for 7 days by celltiter-glo 3D assay	[PMID: 38206836]
PANC-1	IC₅₀	17.8 nM Compound: BI-3406	Antiproliferative activity against human PANC-1 cells harboring KRAS G12D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human PANC-1 cells harboring KRAS G12D mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
PC-3	IC₅₀	1.37 μM Compound: BI-3406	Synergistic antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of gefitinib by MTT assay Synergistic antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of gefitinib by MTT assay	[PMID: 38630077]
PC-3	IC₅₀	8.75 μM Compound: BI-3406	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 38630077]
SW-620	IC₅₀	30.1 nM Compound: BI-3406	Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant assessed as inhibition of cell proliferation incubated for 7 days by CellTiterGlo-3D proliferation assay	[PMID: 36897932]
SW-620	IC₅₀	50.5 nM Compound: 1; BI-3406	Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant assessed as inhibition of cell growth Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant assessed as inhibition of cell growth	[PMID: 38714262]

In Vitro

BI-3406 is an inhibitor of the interaction between KRAS and its Guanine Nucleotide Exchange Factor (GEF) SOS1. BI-3406 does not block the interaction of KRAS with SOS2 but elicits activity on a broad panel of KRAS oncogenic variants, including all major G12 and G13 oncoproteins. Down-modulation of this signaling cascade by BI-3406 in KRAS G12 or G13 mutant cells effectively limits cell proliferation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

462.46

Formula

C₂₃H₂₅F₃N₄O₃

CAS No.

2230836-55-0

Appearance

Solid

Color

White to off-white

SMILES

CC1=NC(N[C@@H](C2=CC(C(F)(F)F)=CC(N)=C2)C)=C3C=C(O[C@@H]4COCC4)C(OC)=CC3=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (216.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 100 mg/mL (216.23 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1623 mL	10.8117 mL	21.6235 mL
5 mM	0.4325 mL	2.1623 mL	4.3247 mL
10 mM	0.2162 mL	1.0812 mL	2.1623 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.41 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 5

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 6

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.95%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (253 KB) HNMR (273 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Michael Gmachl, et al. Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors. WO2018115380A1.

[2]. Marco H Hofmann, et al. Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors. December 2019.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	2.1623 mL	10.8117 mL	21.6235 mL	54.0587 mL
	5 mM	0.4325 mL	2.1623 mL	4.3247 mL	10.8117 mL
	10 mM	0.2162 mL	1.0812 mL	2.1623 mL	5.4059 mL
	15 mM	0.1442 mL	0.7208 mL	1.4416 mL	3.6039 mL
	20 mM	0.1081 mL	0.5406 mL	1.0812 mL	2.7029 mL
	25 mM	0.0865 mL	0.4325 mL	0.8649 mL	2.1623 mL
	30 mM	0.0721 mL	0.3604 mL	0.7208 mL	1.8020 mL
	40 mM	0.0541 mL	0.2703 mL	0.5406 mL	1.3515 mL
	50 mM	0.0432 mL	0.2162 mL	0.4325 mL	1.0812 mL
	60 mM	0.0360 mL	0.1802 mL	0.3604 mL	0.9010 mL
	80 mM	0.0270 mL	0.1351 mL	0.2703 mL	0.6757 mL
	100 mM	0.0216 mL	0.1081 mL	0.2162 mL	0.5406 mL

BI-3406 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

BI-3406

Customer Review

11 Publications Citing Use of MCE BI-3406

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Ras Isoform Specific Products:

View All p38 MAPK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

BI-3406 Related Classifications

Keywords:

Your Recently Viewed Products:

BI-3406

Customer Review

BI-3406 Related Antibodies

11 Publications Citing Use of MCE BI-3406

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Ras Isoform Specific Products:

View All p38 MAPK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

BI-3406 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

BI-3406 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report